Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-04-18
2006-04-18
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S018700
Reexamination Certificate
active
07030089
ABSTRACT:
Compounds which are α-halogenoacryloyl distamycin derivatives of formula (I) wherein R1is a bromine or chlorine atom; R2is a distamycin or distamycin-like framework as set forth in the specification; or a pharmaceutically acceptable salt thereof; are cytotoxic agents particularly effective in the treatment of tumors over expressing GSH/GSTs system and which are poorly responsive or even resistant to conventional antitumor therapies.
REFERENCES:
patent: 5646177 (1997-07-01), Koch et al.
patent: 5880097 (1999-03-01), Lyttle et al.
patent: 0 246 868 (1987-11-01), None
patent: 0 265 719 (1988-05-01), None
patent: 0 388 948 (1990-09-01), None
patent: 0 420 121 (1991-04-01), None
patent: 2 178 036 (1987-02-01), None
patent: WO 90 11277 (1990-10-01), None
patent: WO 96 05196 (1996-02-01), None
patent: WO 97 28123 (1997-08-01), None
patent: WO 97 43258 (1997-11-01), None
patent: WO 98 04524 (1998-02-01), None
patent: WO 98 21202 (1998-05-01), None
patent: WO 99 34796 (1999-07-01), None
patent: WO 99 50265 (1999-10-01), None
patent: WO 99 50266 (1999-10-01), None
patent: WO 00 06541 (2000-02-01), None
patent: WO 00 06542 (2000-02-01), None
patent: WO 01 40181 (2001-06-01), None
patent: WO 01 85144 (2001-11-01), None
D'Alessio, Roberto et al: “Structure-activity relationship of novel distamycin A derivatives: Synthesis and antitumor activity” Bioorg. Med. Chem. Lett. (1994), 4(12), 1467-72, XP000671766.
Colella, G. et al: “Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents” Br. J. Cancer (1999), 80(3/4), 338-343, XP001039733.
Giusti Anna Maria et al: “In vivo induction of apoptosis with PNU-166196 in human ovarian carcinoma xenogratfs.” Proceedings of the American Association for Cancer Research Annual, No. 41, Mar. 2000, p. 825 XP001039865 91st Annual Meeting of the American Association for Cancer Research.: San Francisco, California, USA; Apr. 1-5, 2000, Mar., 2000 ISSN: 0197-016X.
Geroni Cristina et al: “Antitumor activity of PNU-166196, a novel DNA minor groove binder selected for clinical development.” Proceedings of the American Association for Cancer Research Annual, No. 41, Mar. 2000, pp. 425-426, XP001039861 91st Annual Meeting of the American Association for Cancer Research.: San 2000, Mar., 2000 ISSN: 0197-016X.
Baraldi, Pier Giovanni et al: “Synthesis and antitumor activity of novel distamycin derivatives” Bioorg. Med. Chem. Lett. (1996), 6(11), 1241-1246 XP004134862 p. 1241, paragraph 2 example SCHEME1 p. 1244, paragraph 1 table 1 p. 1244, paragraph 4—p. 1245, paragraph 1.
Stewart D J et al: “Non-Chemotherapeutic Agents that Potentiate Chemotherapy Efficacy” Cancer Treatment Reviews, vol. 16, No. 1, 1989, pp. 1-40, XP001039737 ISSN: 0305-7372 p. 18, paragraph 3—p. 19, paragraph 1.
Tsuchida S et al: “Elevation of the Placental Glutathione-S-Transferase Form GST-PI in Tumor Tissues and the Levels in Sera of Patients with Cancer” Cancer Research, vol. 49, No. 18, 1989, pp. 5225-5229, XP001039783 ISSN: 0008-5472 abstract p. 5225, col. 1, paragraph 1 p. 5228, col. 1, paragraph 1 p. 5228, col. 2, paragraph 2.
Cozzi P: “A new class of cytotoxic DNA minor groove binders: alpha-halogenoacrylic derivatives of pyrrolecarbamoyl oligomers.” FARMACO, (Jan.-Feb. 2001) 56 (1-2) 57-65., XP001039805 abstract p. 58, col. 2, paragraph 4 p. 59, col. 1, paragraph 1 figure 5 p. 60, col. 1, paragraph 2—p. 61, col. 1, paragraph 4 tables 2,3 p. 62, col. 2, paragraph 3 figures 9, 10 table 5 p. 63, col. 1, paragraph 1—col. 2, paragraph 2.
Geroni C et al: “PNU-166196: A novel antitumor agent whose cytotoxicity is enhanced in tumor cells with high levels of glutathione.” Tumori, vol. 86, No. 4 Suppl. 1, Jul. 2000, pp. 41-42, XP001039871 XV Congress of the Italian Cancer Society; Turin, Italy; Oct. 5-7, 2000 ISSN: 0300-8916.
Cozzi, Paolo et al: “Cytotoxic.alpha.—bromoacrylic derivatives of distamycin analogs modified at the amidino moiety” Bioorg. Med. Chem. Lett. (2000), 10(11), 1273-1276 , Jun. 2000, XP004200573 abstract p. 1273, col. 1, paragraph 3—col. 2, paragraph 1 table 1 p. 1274, col. 2, paragraph 3—paragraph 4 p. 1275, col. 1, paragraph 3—col. 2, paragraph 2.
Baraldi, Pier Giovanni et al: “Synthesis and Antitumor Activity of New Benzoheterocyclic Derivatives of Distamycin A” J. Med. Chem. (2000), 43(14), 2675-2684, Jul. 13, 2000, XP001039581 abstract p. 2676, col. 1; tables p. 2676, col. 1, paragraph 1 tables 1, 2 p. 2678, col. 2, paragraph 5—p. 2679, col. 1, paragraph 1 p. 2680, col. 2, paragraph 3.
Sola F et al: “The antitumor efficacy of cytotoxic drugs is potentiated by growth-factor-complexing molecule” Cancer Chemotherapy and Pharmacology, vol. 43, No. 3, 1999, pp. 241-246, XP002104215. ISSN: 0344-5704.
Zou J P et al: “Distamycin A derivatives potentiate tumor-necrosis factor activity via the modulation of tyrosine phosphorylation” International Journal Fo Cance, New York, NY, US, vol. 72, No. 5, 1997, pp. 810-814, XP002104217 ISSN: 0020-7136.
Tagliabue G et al: “Combination of the New Minor Groove Alkylator Tallimustine and Melphalan” European Journal of Cancer, Pergamon Press, Oxford, GB, vol. 33, No. 2, Feb. 1997, pp. 284-287, XP004282511 ISSN: 0959-8049.
Boger et al., “Total Synthesis of Distamycin A and 2640 Analogues: A Solution-Phase Combinatorial Approach to the Discovery of New Bioactive DNA Binding Agents and Development of a Rapid, High-Throughput Screen for Determining Relative DNA Binding Affinity or DNA Binding Sequence Selectivity”, J. Am. Chem. Soc. 2000. 122. 6382-6394.
Cozzi P et al: “Cytotoxic halogenoacrylic derivatives of distamycin A” Bioorganic & Medicinal Chemistry Letters, oxford, GB, vol. 10, No. 11, Jun. 2000 (200-06), pp. 1269-1272, XP004200572 ISSN: 0960-894X.
Mosconi A M et al: XP004282426 “Combination Therapy with Gemcitabine in Non-Small Cell Lung Cancer” European Journal of Cancer , Pergamon Press, Oxford, GB, vol. 33, Jan. 1997, pp. S14-S17, ISSN: 0959-8049.
Catharina J A Van Moorsel et al: XP002110339 “Gemcitabine: Futrue Prospects of Single-Agent and Combination Studies” Oncologist, Alphamed Press, US, vol. 2, No. 3, 1997, pp. 127-134, ISSN: 1083-7159.
Budavari S (ED): XP002191966 “The Merck Index (12th Edition)” Merck Index, Encyclopedia of Chemicals, Drugs, and Biologicals, 13th. Edition 1996, Whitehouse Station, Merck & Co, US, vol. ED. 13, 2001, p. 4206 ISBN: 0-911910-12-3.
Beria Italo
Cozzi Paolo
Geroni Maria Cristina
Pharmacia Italia S.p.A.
Russel Jeffrey Edwin
Scully Scott Murphy & Presser
LandOfFree
Use of substituted acryloyl distamycin derivatives in the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of substituted acryloyl distamycin derivatives in the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of substituted acryloyl distamycin derivatives in the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3595057